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ABSTRACT
The Leahy-Smith America Invents Act of 2011 (AIA)
makes fundamental changes to the legislative landscape
governing patent law in the United States and will bring
about corresponding changes in the manner in which
inventors and attorneys address patent issues. While the
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law is newly implemented, inventors in all sectors of the
economy are eager to formulate reactions to it. In this
Article, we explore the effects of the AIA on nonprofit
research organizations dedicated to global health and life
sciences. We report the perspectives of counsel
representing such organizations throughout the Pacific
Northwest. We also consider the patent system, and the
Act’s effects on the system, in the context of scientific and
humanitarian motivations.
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INTRODUCTION
Imagine the following scenario: A technology manager at a
nonprofit bioscience research organization contacts her
institution’s patent counsel, excited to share an extremely
promising advance from one of her labs—a new adjuvant system
that greatly increases the efficacy of a developmental tuberculosis
vaccine. The system works so well that she is certain that a large
pharmaceutical company will pay a significant licensing fee for the
technology. All that is needed, she thinks, is to file a patent
application to protect the invention and help secure the funding
required to deliver a new vaccine system to at-risk populations
around the world. Additionally, this deal will provide crucial
funding for the organization in a difficult economy.
Tragically, the benefits of this invention may not be realized.
The researcher who developed the new system neglected to inform
the technology manager about a symposium presentation during
the invention’s early stages, about a year ago. Cognizant of the
existing patent laws, he did not distribute any printed publications
regarding his invention, but a slideshow featuring his abstract was
accessible on the symposium website for an undetermined length
of time. Under the newly implemented America Invents Act
(AIA), the invention may be considered available to the public for
over a year and therefore not patentable. As a consequence of
failing to file an application until after March 16, 2013, the
nonprofit organization could lose out to a wealthier applicant—
perhaps its potential licensee—under the new “first-inventor-tofile” priority system. With no patent to protect its intellectual
property, the nonprofit loses control over a licensable technology,
cannot attract investment to develop or deliver the adjuvant where
it will do the most good, and loses a valuable source of revenue.
This hypothetical, while somewhat simplistic and dramatic,
illustrates the potential impact of the AIA on inventors in the
nonprofit sectors.
Part I of this Article discusses the statutory and historical
backdrop of both the U.S. patent system and the AIA. Part II
examines nonprofit research organizations as innovators within the
patent system and describes our inquiry into the AIA’s effects—
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real, perceived, or anticipated—on these innovators. This inquiry
focuses on five aspects of the AIA that we identified as being of
special concern to nonprofits. In Part III, we discuss the results of
our qualitative survey on the aforementioned effects of the AIA on
nonprofit innovators, as described by the in-house and outside
counsel who represent such innovators in the Pacific Northwest.
I. THE U.S. PATENT SYSTEM AND THE AMERICAN INVENTS ACT
A. Innovation and the U.S. Patent System
Innovation has been celebrated in the United States since the
Founding. It has been called “the key driver of competitiveness,
wage and job growth, and long-term economic growth,” 1 and this
valuation has resulted in an advanced system of intellectual
property laws designed to foster innovation, as a mechanism for
advancing society, by rewarding individual efforts.
In that spirit, the drafters of the Constitution empowered
Congress “[t]o promote the Progress of Science and useful Arts, by
securing for limited Times to Authors and Inventors the exclusive
Right to their respective Writings and Discoveries.” 2 The resulting
intellectual property laws enacted by Congress protect exclusive
rights that are expressed in copyright, 3 trademarks, 4 and patents. A
patent is an exclusive government-granted exclusive right to make,
use, sell, or offer to sell a claimed invention for a limited time. 5
The rightful holder of a patent is empowered to sell or license the
patent, or to sue for damages or an injunction when the right is
infringed. For a patent to issue, the invention must meet certain
utility, novelty, and nonobviousness requirements as determined
1

U.S. Dep’t of Commerce, The Competitiveness and Innovative Capacity
of the United States (Jan. 2012) at 9, http://www.commerce.gov/sites/
default/files/documents/2012/january/competes_010511_0.pdf.
2
U.S. CONST. art.1, § 8, cl. 8.
3
See 17 U.S.C. § 102(a) (2006) (copyright given to the author of original
works that are fixed and reproducible).
4
See 15 U.S.C. § 1127 (2006) (trademark protects a “word, name, symbol,
or device” identifying unique goods).
5
AMY L. LANDERS, UNDERSTANDING PATENT LAW 1 (LexisNexis, 2nd ed.
2012) (defining “practicing” a patent).
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by an examiner at the United States Patent and Trademark Office
(USPTO). 6 A patent application to the USPTO must also contain
“one or more claims particularly pointing out and distinctly
claiming the subject matter which the inventor or joint inventor
regards as the invention.” 7 Claims define the patented invention
and determine its operative legal effect. 8 If a patent issues, the
holder obtains an exclusive right to the invention for twenty years
from the initial filing date of the application.
In a global marketplace, the value of exclusive rights to an
invention is potentially massive. A recent study showed that the
2,000 largest global companies invested more than $640 billion in
research and development in 2008. 9 In the United States, the
number of patents issued annually has increased from roughly
70,000 in the 1980s to well over 200,000 in the 2000s, with over 8
million total patents issued since the late eighteenth century. 10 In
the short term, this trend looks set to continue. 11
6

A patentable invention is one that is truly novel, provides a function, and
is not obvious, in light of previous knowledge, to an inventor of ordinary skill in
the art. See U.S. Patent and Trademark Office (USPTO), Novelty and
Nonobviousness, Conditions for Obtaining a Patent (Nov. 2011),
http://www.uspto.gov/
patents/resources/general_info_concerning_patents.jsp#heading-5. See also 35
U.S.C. § 112(a) (requiring a “written description of the invention, and of the
manner and process of making and using it, in such full, clear, concise, and
exact terms as to enable any person skilled in the art to which it pertains”)
(emphasis added).
7
35 U.S.C. § 112(b) (2006).
8
LANDERS, supra note 5, at 57.
9
Joint Research Centre (EC), INSTITUTE FOR PROSPECTIVE
TECHNOLOGICAL STUDIES, The 2009 EU Industrial R&D Investment
Scoreboard,
at
16,
(2009),
http://iri.jrc.ec.europa.eu/scoreboard09.
html;jsessionid=py3jSywRGLKbzyBl4vrGv452FddZzjW9D9FdT7ysvyDnyRL
gljpX!-573964881!1390997617993. We converted the figure from euros to U.S.
dollars using the average conversion value for the year 2008, calculated using
data
from
X-Rates,
available
at
http://www.x-rates.com/average/
?from=EUR&to=USD&amount=1.00&year=2008.
10
USPTO, U.S. Patent Activity, Calendar Years 1790 to the Present.
http://www.uspto.gov/web/offices/ac/ido/oeip/taf/h_counts.htm (last visited Feb.
6, 2014).
11
See Dennis Crouch, USPTO Grant Rate: 2013 Forecast, PATENTLYO
(Jan. 8, 2013, 11:19 AM), http://www.patentlyo.com/patent/2013/01/uspto-
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B. Legislative Background and Context
As patent activity in the United States has grown in scope and
intensity, evolution has been necessary to achieve positive societal
outcomes through a system predicated on private incentives. Since
the Patent Act of 1790, the system has undergone continual
amendment, with the last major changes made in 1952. 12 Recently,
commentators have cited the high costs of litigation, common
abuses of the patent system, 13 and the divide between U.S. and
foreign practices to justify further legislative address. 14
To that end, some legislators attempted revisions via the
proposed Patent Reform Acts of 2005, 2007, and 2009. Various
provisions in these bills attempted to decrease the overall costs and
sheer amount of patent litigation while raising the quality,
efficiency, and international compatibility of the patent system.15
However, it was not until January 2011 that Senators Patrick
Leahy of Vermont and Lamar Smith of Texas co-sponsored a
successful bill, enacted as the AIA in September of that year. 16 The
AIA’s central provisions took effect on March 16, 2013.
Given its economic significance, the bill was unsurprisingly
grant-rate-2013-forecast.html (stating that the USPTO, shortly after issuing a
single-day record of 5,633 utility patents on Jan. 8, 2013, projects issuing a
record 290,000 patents this year).
12
US Patents—A Brief History, THE BUSINESS OF PATENTS (Feb 7, 2014),
http://www.the-business-of-patents.com/us-patents.html.
13
One common complaint among small inventors is that frivolous lawsuits
filed by larger entities (often non-practicing entities or “patent trolls”) stifle
innovative progress because inventors spend valuable resources defending
against the claim that would be better spent on R&D. See Ben Lee, Twitter: It’s
time for patent trolls to bear the cost of frivolous lawsuits, GIGAOM (Oct. 8,
2012, 6:00 AM), http://gigaom.com/2012/10/08/twitter-time-for-trolls-to-payfull-price-for-patent-mischief. See also Charles Duhigg and Steve Lohr, The
7,
2012),
Patent,
Used
as
a
Sword, N.Y. TIMES (Oct.
http://www.nytimes.com/2012/10/08/technology/patent-wars-among-techgiants-can-stifle-competition.html?pagewanted=all.
14
Jason Rantanen, Lee Petherbridge & Jay P. Kesan, America Invents,
More or Less?, 160 U. PA. L. REV. 229 (2012).
15
Patent Reform Act of 2009, GOVTRACK.US, https://www.govtrack.us
/congress/bills/111/s515#summary (last visited Feb. 3, 2014).
16
See A Companion to Science and Engineering Indicators 2008, NAT’L
SCIENCE BD. (Jan. 2008), http://www.nsf.gov/statistics/nsb0803/start.htm.
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subject to intense lobbying efforts as it wound its way through
Congress. Large corporations in the financial services,
pharmaceutical, and computer/telecommunications industries were
strong proponents of the proposed AIA. Notably in favor were
such established entities as Microsoft, IBM, GE, Caterpillar, Dow
Chemical, PepsiCo, and Procter & Gamble. 17 Newer technology
industry actors, including Google, Apple, Yahoo!, and eBay
favored the move to “first-to-file” but disapproved of the proposed
legislation because they feared it would raise the costs of the patent
challenge system, ultimately detracting from valuable research and
development (R&D) efforts. 18
In notable opposition to the AIA, the National Small Business
Association (NSBA) claimed that the law was severely tilted
“against small innovators and in the favor of large, multinational
corporations.” 19 According to the NSBA, small entities are the
most efficient drivers of the patent system, but are greatly
disadvantaged under a first-to-file regime, which favors large
companies that can quickly file fully developed applications.20
Many commentators shared this concern. 21 Further, the NSBA
interpreted the AIA to “gut” a one-year grace period prior to filing
a patent application, during which inventors could raise capital and
create partnerships without fear that disclosures would become
prior art. 22 Thus, some tension existed between small and big
17

See Kurt Mackie, Q&A: A Patent Attorney Explains How the ‘America
Invents Act’ Will Affect Tech, REDMOND MAGAZINE (Sep. 20, 2011), available
at http://redmondmag.com/articles/2011/09/20/impact-of-america-invents-ontech.aspx.
18
Id.
19
Nat’l Small Bus. Ass’n, NSBA Cautions Lawmakers Against Patent
Reform, (Sep. 7, 2011) http://www.nsba.biz/content/4181.shtml.
20
Nat’l Small Bus. Ass’n, Patent Reform: Small business concerns are
fundamental to any discussion concerning patent reform (May 2012),
http://www.nsba.biz/wp-content/uploads/2012/05/Patent-Reform.pdf.
21
See, e.g., Clyde Prestowitz, The Prevent American Invention Act,
POLICY
(May
16,
2011),
available
at
FOREIGN
http://prestowitz.foreignpolicy.com/posts/2011/05/16/the_prevent_american_inv
ention_act.
22
Nat’l Small Bus. Ass’n, Patent Reform Bill Will Crush Small-Business
LATEST
NEWS
(June
22,
2011),
Innovation,
NSBA
http://www.nsba.biz/content/4008.shtml.
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business with respect to the AIA. The perspective the academic
and nonprofit sectors, another significant innovating community,
did not receive as much attention.
II. THE POTENTIAL IMPACT OF THE AIA ON
NONPROFIT INNOVATION
Nonprofit innovators at government entities, independent
research centers, foundations, hospitals, and universities operate
under much different circumstances—and often with quite
different goals—than their counterparts in the for-profit world.
From bone marrow transplants to satellite communication,
nonprofit entities have made significant inventive contributions to
many vital technological fields. 23 If applying technology to solve
compelling problems is a desired outcome of the patent system,
then any assessment of that system must consider the state of
medicine and public health.
While for-profit companies typically mass-produce and bring
therapeutics to the commercial market, most of the basic research
advancing health science in this country is conducted at publicly
funded universities and other nonprofit research centers. 24 These
23

For example, the first successful bone marrow transplant was conducted
at the Fred Hutchinson Cancer Research Center by Dr. E. Donnell Thomas in
1956, see Fred Hutchinson Cancer Research Ctr., Impact of Dr. E. Donnall
Thomas’s
Work,
http://www.fhcrc.org/en/about/honors-awards/nobellaureates/thomas/thomas-impact.html (last accessed Mar. 30, 2013), while work
at the National Aeronautics and Space Administration (NASA) has produced or
led to such advances as water filters, adjustable smoke alarms, cochlear
implants, insulin pumps, arterial imaging technology, and major advances in
long-distance telecommunications. See, e.g., Patrick J. Kiger and Marianne
English,
Top
10
NASA
Inventions,
HOWSTUFFWORKS,
http://www.howstuffworks.com/innovation/inventions/top-5-nasainventions.htm#page=3 (last accessed Apr. 4, 2013).
24
See Nat’l Sci. Found., A Companion to Science and Engineering
Indicators 2008, (Jan., 2008), http://www.nsf.gov/statistics/nsb0803/start.htm
(“Federal funding is the primary source of basic research support in the U.S.
(over 59% in 2006), of which about 56% is carried out by academic institutions.
U.S. basic research is also funded by foundations (about 10%), universities and
colleges (about 10%), and state and local governments (about 3.5% through
funding of academic basic research”)).
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research institutions make notable contributions to economic
activity25 and play a major role in commercializing early-stage
inventions. 26 Although nonprofit organizations freely disseminate
much of their work for the benefit of the public, substantial
benefits can be realized when discoveries from nonprofit research
enter the commercial sector for development into useful products
and processes. The landmark 1980 Bayh-Dole Act 27 has been an
extraordinarily successful mechanism for facilitating the transfer of
basic discoveries into the commercial sector for development. 28
The general goals of nonprofit research institutions are to
increase the scope of knowledge in relevant fields; publish findings
25

Nonprofit research organizations have contributed between $199-$836
billion of U.S. gross domestic product from 1996-2010. See Lori Pressman et
al., The Economic Contribution of University/Nonprofit Inventions in the United
States: 1996-2010, BIOTECHNOLOGY IND. ORG. (June 20, 2012),
http://www.bio.org/sites/default/files/BIOEconomicImpact2012June20.pdf.
26
Frank X. Curci, Life Sciences: Changes in patent law challenge nonprofit
bioscience institutions, PUGET SOUND BUS. J., July 13, 2012,
http://www.bizjournals.com/seattle/print-edition/2012/07/13/life-scienceschanges-in-patent-law.html?page=all.
27
Pub. L. 96-517 (authorizing universities and small businesses to retain
patent and licensing rights to inventions resulting from federally funded research
and requiring recipients of federal funds “to maximize the use of their research
findings by making them available to the research community and the public at
large and through their timely and effective transfer to industry for
development.”). See also NATIONAL INSTITUTES OF HEALTH, Developing
Sponsored Research Agreements: Considerations for Recipients of NIH
Research Grants and Contracts. 59 Fed. Reg. 55673, 55674–79, Nov. 8, 1994,
available at http://grants.nih.gov/grants/guide/notice-files/not94-213.html (last
accessed Feb. 7, 2013).
28
See Memorandum from the Ass’n of Am. Univ. et al. to Office of Sci.and
Tech. Policy and Nat’l Econ. Council on Commercialization of Univ. Research
(May
10,
2010),
available
at
http://www.aau.edu/WorkArea/
DownloadAsset.aspx?id=10808 (noting that prior to 1981 fewer than 250
patents were issued to United States universities annually, and laboratory
discoveries were seldom commercialized for the public benefit). See also
Association of University Technology Managers U.S. Licensing Activity Survey
Highlights (2011), http://www.autm.net/AM/Template.cfm?Section=FY_2011_
Licensing_Activity_Survey&Template=/CM/ContentDisplay.cfm&ContentID=
8731 (finding that 4,700 United States patents were issued to United States
universities during 2011, while 671 new start-up companies were formed and
591 new products were introduced based upon university inventions).
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and secure further funding; and, depending on the institution,
implement the findings to solve the problem. The governing
objective for many nonprofit health science organizations is to
treat or eradicate diseases such as cancer, tuberculosis, or malaria
through therapeutics, vaccines, public health mechanisms, or other
means. The nonprofit model subsumes economic gain to problemsolving goals. Nonetheless, licensing technology plays an
important role in the nonprofit sector because licensing technology
to commercial actors for development and introduction to market
is mutually beneficial for both nonprofit and commercial actors.
Patents are critical to enabling this process. Identifying,
cultivating, and selling commercially successful health science
products is an extremely expensive and risky process 29 involving
numerous failed candidates and experimental setbacks. 30 For a
nonprofit to realize the promise of a given innovation, it must be
marketed to commercial partners as a viable, low-risk investment.
The security of the innovation’s intellectual property mitigates the
risk of an investment. Nonprofits, therefore, are motivated to
protect their intellectual property.
Other features of nonprofit bioscience research organizations
distinguish them from similar innovating communities as well.
While curing a certain disease may be a nonprofit research
organization’s mission, innovation in furtherance of that mission is
largely practiced by academic scientists, whose individual aims
may diverge from those of the parent organization. The time a
researcher spends with a given organization may be relatively short
(graduate or fellowship tenures often range from three to six
29

The average input cost for a commercially available drug is in excess of
$1 billion. See Roger Collier, Drug development costs hard to swallow, CAN.
MED.
ASS’N.
JOURNAL
(Feb.
3,
2009),
available
at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630351/pdf/20090203s00009p
279.pdf.
30
More than 6,000 completely new chemical compounds are synthesized
for every one drug that ultimately comes to market. See Gregory A. Petsko,
When failure should be the option, BIOMEDCENTRAL (May 21, 2010),
http://www.biomedcentral.com/1741-7007/8/61. See also Sandra Krajlevic,
Peter J. Stambrook & Kresimir Pavelic, Accelerating drug discovery, EMBO
REPORTS
(Sept.
2004),
http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC1299137.
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years). In that context, these scientists are incentivized to publish
their work as a primary goal. Disclosing a promising development
can enhance a researcher’s career and advance scientific
knowledge. Thus, most researchers are not as concerned with
exploring commercial opportunities as they are with producing
quality research and securing research funding. 31
As such, the major aims of the innovators and the nonprofit
research entity they innovate “for” are sometimes imperfectly
matched. These factors, in the context of commercial and legal
realities, create a unique set of considerations regarding intellectual
property protection. The leadership and administration of such
organizations, as well as the attorneys who counsel them, must
assess intellectual property practices against the nonprofits’ goals
and limited resources. 32 A high concentration of nonprofit research
31

This assertion is based on the Authors’ respective experiences in
academic science and the opinions of our survey respondents.
32
A complete exploration of the patent system and its role in promoting
positive advances necessarily encompasses an examination and critique of
whether patents are a necessary or even desirable way to spur innovation. This
Article assumes that patent law is a fixed construct in our social landscape, and
that it does provide certain benefits and incentives to innovators across the forprofit and nonprofit spectrum. Our scope is accordingly limited to how
nonprofits can best operate and how systemic changes affect nonprofit research.
However, there are certainly examples of unpatented biotechnology benefitting
the world (e.g., the polio vaccine was never patented), and many serious
criticisms of the patent system exist. Critics claim, for example, that patents
reward the already wealthy, monopoly slows innovation and worthy uses of
technology, bad patents on already-known inventions are commonly issued,
patents permit non-practicing entities to depress the efficacy and affordability of
using technology, patents on human genes or food products are unfavorable for
a number of reasons, patents reward only incremental improvements in
pharmaceutical products, rather than actually solving health problems, and that
such patents raise drug costs to prohibitive levels, depriving the poor from that
benefit and enriching shareholders in large pharmaceutical companies. See
generally Richard A. Posner, Why There Are Too Many Patents In America,
THE ATLANTIC (July 12, 2012), http://www.theatlantic.com/business/archive/
2012/07/why-there-are-too-many-patents-in-america/259725/.
Inventors may choose alternatives to patenting, such as publishing
defensively to prevent a patent by another and providing the invention freely to
the world, providing federal “prize money” to compensate inventors for
forgoing a patent monopoly, pursuing exclusive licenses to ensure that
customers do not use a competing product but permitting others to use the idea,
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and funding organizations is found in the Pacific Northwest, 33
including the Bill & Melinda Gates Foundation, the University of
Washington, Fred Hutchinson Cancer Research Center, the
Infectious Disease Research Institute, Washington State
University, Seattle Biomedical Research Institution, PATH, Seattle
Children’s Research Hospital, Oregon Health Sciences University,
and the Institute for Systems Biology. These entities focus on
advancing science and solving worldwide public health issues.
To create our survey, we identified five aspects of the AIA
likely to most impact these and similar nonprofit research
organizations: (i) The transition from a “first-to-invent” to a “firstinventor-to-file” (FITF) system, (ii) the prior commercial use
defense to infringement claims and accompanying university
exception, (iii) the expanded definition of prior art and changes to
the inventor’s one-year pre-filing grace period, (iv) the amended
third party patent challenge system, and (v) the implementation of
derivation proceedings and new post-grant challenge procedures.
We will present each of these aspects of the AIA before discussing
the survey response data.
A. First-Inventor-to-File
Among the most significant changes under the AIA is a shift
from a first-to-invent system to an FITF system, which went into
effect on March 16, 2013. 34 Prior to the AIA, the United States
issued patents based on a first-to-invent system, whereby patent
priority went to the first inventor in fact, rather than to the first
inventor to file for a patent. 35 In contrast, the AIA awards patent
and implementing “utility models,” which have a shorter duration and are
cheaper and easier to obtain. See, e.g., World Intellectual Prop. Org., Protecting
Innovations by Utility Models, http://www.wipo.int/sme/en/ip_business/
utility_models/utility_models.htm (last visited Feb. 6, 2014).
33
A recent tally listed over 40 biology focused nonprofits, academic
institutions, and support organizations in the region. See Stewart Lyman, Seattle
(NW) Biotechnology Resource Page, LYMAN BIOPHARMA CONSULTING LLC,
http://www.lymanbiopharma.com/seattlebionon-profits.html (last visited Feb. 6,
2014).
34
H.R. 1249 § 3(b), 112th Cong. (2011).
35
35 U.S.C § 102(g) (1952).
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rights to the first inventor to file, thereby placing a premium on
filing as soon as possible. Whether the first applicant actually
represents the first completion of the invention is irrelevant. 36 This
system comports with similar first-to-file patent systems in most
other countries.
International harmonization was a key goal of the AIA, but the
United States’ FITF system is discernible from the traditional
international first-to-file system. 37 Under a traditional first-to-file
system, absolute novelty is required in order to obtain a patent; that
is, no patent can be granted if there is a prior use or publication of
information relating to the invention. 38 By contrast, the AIA
maintains a one-year grace period, dating back from the inventor’s
filing date, wherein certain disclosures of the invention will not bar
patentability. This grace period has been modified and is addressed
in Part II(d).
In addition, the “effective filing date” under the AIA is either
the actual filing date of the nonprovisional application or the filing
date of the provisional application that the applicant is entitled to
claim. 39 While a provisional application cannot result in a patent,
under a relation-back theory, the application gives a later

36

Wendy H. Schact & John R. Thomas, The Leahy-Smith America Invents
Act: Innovation Issues, Cong. Research Serv., C.R.S. R4201 (2013), available at
https://www.fas.org/sgp/crs/misc/R42014.pdf.
37
Wendell Ray Guffey & Kimberly Schreiber, America Invents Act: The
Switch to a First-to-File, 68 J. Mo. B. 156 (2012), available at
http://www.mobar.org/uploadedFiles/Home/Publications/Journal/2012/0506/invents-act.pdf.
38
See Gene Quinn, America Invents: A Simple Guide to Patent Reform,
(January
9,
2013,
12:30
PM),
Part
1,
IPWATCHDOG
http://www.ipwatchdog.com/2011/09/26/america-invents-a-simple-guide-topatent-reform-part-1/id=19427/.
39
The various circumstances that can determine the appropriate filing date
are described in under 35 U.S.C. §§ 119, 120, 121, or 365(a)-(c). H.R. 1249 §3
(2011). A provisional application must include a specification and drawing, but
does not need to include a claim. See 35 U.S.C. § 111(b) (2011). In contrast, a
nonprovisional application must include a specification, a drawing, and an oath
and be accompanied by the appropriate fee and signed by the inventor. 35
U.S.C. § 111. The specification of a nonprovisional must include one or more
distinct claims about the invention. 35 U.S.C. § 112(b) (2011).
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nonprovisional application the benefit of the provisional filing date
for priority purposes.
B. Prior Commercial Use and the University Exception
Predating the AIA, the American Inventors Protection Act of
1999 provided a “prior commercial use” defense against
infringement claims for commercial users of a “method of doing or
conducting business” that was later patented by another. 40 If a
company retained an invention as a trade secret, 41 and a competitor
later created and patented the invention, the first company would
be able to raise the prior commercial use defense against an
infringement claim and thus continue using the method. Without
this defense, a trade secret owner accused of infringement would
have to choose whether to pay a licensing fee to the patent holder
or pursue litigation to invalidate the patent.
The AIA expands the prior commercial use defense beyond the
scope of business method patents to include any type of
invention. 42 That is, the defense is now available to persons who
independently employed the invention in the United States in
connection with an internal commercial use, an arm’s length sale,
or an arm’s length transfer of a useful end result of the commercial
use. 43 This defense, however, is subject to limitations and
exceptions. It is personal and may not be licensed, assigned, or
40

USPTO, Report on the Prior User Rights Defense, Report to Congress at
6 (2012), available at http://www.uspto.gov/aia_implementation/20120113pur_report.pdf
41
Trade secret law is concerned with the protection of technological and
commercial information that is not generally known in the trade against
unauthorized commercial use by others. See Kewanee Oil Co. v. Bicron Corp.,
416 U.S. 470, 473 (1990) (“The subject of a trade secret must be secret, and
must not be of public knowledge or of a general knowledge in the trade or
business.”).
42
35 U.S.C. § 273(a) (2011).
43
USPTO, Report on the Prior User Rights Defense, at 7 (Jan. 2012),
http://www.uspto.gov/aia_implementation/20120113-pur_report.pdf (explaining
that to assert the defense, the prior user must establish that the “relevant
activities occurred more than one year before the earlier of (1) the filing date of
the patent application or (2) the date of public disclosure by the patentee during
the patentee’s grace period.”).
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transferred except as part of a good faith transfer of the entire
entity or of the particular line of business. 44 In the event of such a
transfer, the acquiring party may not expand use of the subject
matter entitled to the defense beyond the original geographic site
of the “prior use.” 45 Further, a special limited exemption is
provided for universities: the prior use defense cannot be used
against universities or university technology transfer
organizations. 46
C. Prior Art Expansion and the Modified One-year Grace Period
Whether an invention is sufficiently novel to receive patent
protection depends on the state of the art in the field. Prior art
under the AIA is any information available to the public before the
time at which the inventor files a patent application. 47 Submitted
applications are vetted by an examiner at the USPTO against art in
the relevant field for patentability, novelty, and nonobviousness. 48
If these and other criteria are met, a patent should issue for an
invention that was not claimed, taught, or made obvious by the
prior art. Otherwise, a patent will not issue or, if improperly issued,
will be invalid. Accordingly, inventors often survey the prior art
before committing to patent prosecution—a costly effort. 49 A
change to the prior art system could seriously impact prosecution
costs and the likelihood of obtaining a patent.
44

Id.
Id.
46
H.R. 1249 § 5. The university exception does not apply “if any of the
activities required to reduce to practice the subject matter of the claimed
invention could not have been undertaken using funds provided by the Federal
Government.” 35 U.S.C. § 273(e)(5)(B).
47
Under the AIA, prior art can take the form of a publication, patent, patent
application, sale, or other public knowledge, use, or offer for sale related to the
invention. See 35 U.S.C. § 102(a)(1).
48
Patent applications are considered for applicable subject matter, novelty
and nonobviousness under 35 U.S.C. §§ 101, 102, and 103, respectively.
49
One notable practitioner prices patent searches at $1200-$2400, and
overall prosecution costs between $5,000 and $15,000. See Gene Quinn, The
Cost of Obtaining a Patent in the U.S, IPWATCHDOG (Jan. 28, 2011),
http://www.ipwatchdog.com/2011/01/28/the-cost-of-obtainingpatent/id=14668/.
45
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Comporting with Congress’s intent to harmonize the new
FITF system with foreign systems, the AIA makes significant
changes to the prior art element. Under the new 35 U.S.C.
§ 102(a), the pool of prior art now includes any public use, sale, or
other disclosure of the invention that renders it “otherwise
available to the public,” measured back from the effective filing
date—in the U.S. or a foreign country—rather than the date of
invention. 50 Novelty and nonobviousness will both be determined
as of the filing date. 51
The new § 102(a) poses multiple challenges for applicants.
First, the expanded international pool of potential prior art means
that applicants must vet their inventions against a wider collection
of information that could be material to patentability. 52 For a
patent to issue, the claimed invention must survive this information
and any other related art before the examiner.
The phrase “or otherwise available to the public” in § 102(a)(1)
further complicates the scope of prior art. Observers have
expressed confusion over its meaning, 53 and question whether the
phrase modifies the preceding “on sale” category—meaning that
public sales, but not secret sales (or unpublished pending
50

Orlando Lopez, The Prior Art Expansion Under the AIA, LEXOLOGY
(Sep. 18, 2012), http://www.lexology.com/library/detail.aspx?g=6e2a1f97-213e42ef-ab22-3e3141f1faa3 (“No longer is the date of invention important — the
important date now is the effective filing date. This change introduces a gamechanging race to the patent office where the first to file wins.”).
51
See, e.g., Jay Pattumudo, The Scope of Prior Art by Others Under AIA
and a Comparison with European and Japanese Patent Law. PATENT BARISTAS
(May 9, 2013), http://www.patentbaristas.com/archives/2013/05/09/the-scopeof-prior-art-by-others-under-aia-and-a-comparison-with-european-and-japanesepatent-law-what-every-scientist-and-corporate-executive-needs-to-know.
52
Lopez, supra note 50.
53
See USPTO, Examination Guidelines for Implementing the First Inventor
to File Provisions of the Leahy-Smith America Invents Act (discussion of Public
Comment
13),
77
Fed.
Reg.
11059
(Feb.
14,
2013),
https://www.federalregister.gov/articles/2013/02/14/2013-03450/examinationguidelines-for-implementing-the-first-inventor-to-file-provisions-of-the-leahysmith#p-238; Pier D. DeRoo & Michael J. Flibbert, Does the AIA Require
Public Availability for “On Sale” Prior Art?, BLOOMBERG LAW REPORTS, Mar.
19,
2012,
available
at
http://www.finnegan.com/resources/articles/
articlesdetail.aspx?news=b78c8ba4-db29-48da-b1ba-ec2119083300.
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applications), continue to be prior art—or stands alone, casting all
sales activity as potential prior art. 54
As an additional consequence of the shift to FITF, inventors
can no longer “swear back” past a prior art reference. Under the
first-to-invent system, an inventor could prove, by sworn affidavit,
an invention date preceding that of a prior art reference. 55 Patent
prosecutors no longer have this strategic tool to help them prove
original inventorship. 56
Section 102(b) defines the exceptions to prior art under
§ 102(a). Previously, inventors enjoyed a one-year grace period,
dated from the filing date, that foreclosed the specter of prior art in
which the claimed invention was published or patented in any
country, or in public use or on sale in the United States. 57 The new
§ 102(b)(1) expands the grace period to include disclosures of the
invention—or subject matter thereof—by the inventor, a joint
inventor, or one who obtained the information from the inventor. 58
The modifications to the grace period have generated
considerable confusion. 59 Some practitioners interpret the statute to
create a “first-to-publish” system whereby publication defeats all
subsequent third-party prior art. 60 Under the USPTO’s proposed
rules of interpretation, however, only those third-party disclosures
that are identical or “substantially identical” to the inventor’s
54

See id. See also Dennis Crouch, Did the AIA Eliminate Secret Prior Art?
PATENTLYO (Oct. 10, 2012), http://www.patentlyo.com/patent/2012/
10/did-the-aia-eliminate-secret-prior-art.html; Matthew R. Osenga, America
Invents Act—Secret Prior Art, INVENTIVESTEP (March 11, 2013, 2:20 PM),
http://inventivestep.net/2013/03/11/america-invents-act-secret-prior-art/.
55
Lopez, supra note 50.
56
See Id.
57
For an excellent side-by-side comparison pre-AIA and AIA provisions,
see Comparison Of Selected Sections Of Pre-AIA and AIA U.S. Patent Law,
PROPERTY
OWNERS
ASS’N
(Oct.
19,
2011),
INTELLECTUAL
http://www.wilmerhale.com/files/upload/IPO_AIA_Chart.pdf.
58
35 U.S.C § 102(b)(1)(b) (2011).
59
See, e.g., Gene Quinn, Defending the USPTO interpretation of the new
grace period, IPWATCHDOG (Sep. 9, 2012), http://www.ipwatchdog.com/2012/
09/09/defending-the-uspto-interpretation-of-the-new-grace-period/id=27903.
60
See, e.g., Letter from Univ. of Cal. Office of Gen. Counsel to Office of
Patent Legal Admin. (Oct. 4, 2012), available at http://www.uspto.gov/
patents/law/comments/uc_20121004.pdf.
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initial disclosure will not be counted as prior art. 61 Any subsequent
disclosure that contains even insubstantial changes from the
original may still count as prior art. 62
Finally, the AIA allows parties to a joint development
agreement to remove one another’s prior art from consideration
when seeking a patent. 63 Under this rule, a nonprofit engaged in a
joint development agreement could file a patent application
without fearing prior art in the form of another partner’s previous
application. This provision was included to promote joint research
activities consistent with the Cooperative Research and
Technology Enhancement (CREATE) Act of 2004. 64
These changes have significant implications for nonprofit
research organizations. Researchers typically present their work
numerous times at lab meetings and public forums culminating in
the publication of an article on their research in an academic
journal. Whether and when an invention is publicly disclosed
greatly affects patentability, and nonprofits seeking to protect
intellectual property must be thoughtful with respect to disclosures.
Changes to the prior art and the one-year grace period add
complexity to these considerations.
These changes also affect patent prosecution. Because of the
changes to prior art, nonprofits may need to perform due diligence
on a larger pool of prior art. The resource demands of these
61

Manual of Patent Examining Procedure (MPEP) § 2112, available at
http://www.uspto.gov/web/offices/pac/mpep/s2112.html.
62
See Arpita Battacharyya, Ph.D. and Eric P. Raciti, The Not-So-Amazing
Grace Period Under the AIA, CIPA JOURNAL (Sep. 2012),
http://www.finnegan.com/resources/articles/articlesdetail.aspx?news=4acad2aa4430-4d87-a197-3a202ac17c5b.
63
35 U.S.C. § 102(c) (2011).
64
See AIA 35 U.S.C. § 102(b)(2) (2011), available at
http://www.govtrack.us/congress/bills/112/hr1249/text. See also Robert A.
Armitage, Understanding the America Invents Act and its Implications for
Patenting, 40 AIPLA Q.J. 1, 24–26 (2012) (“the Cooperative Research and
Technology Enhancement (CREATE) Act of 2004 completed pre-AIA § 103. It
sought to extend “co-worker” benefits of the AIPA to research collaborators by
treating patent filings under joint research agreements as though they had been
commonly assigned. The aggregate result of the pre-AIA amendments to § 103
was that…the AIP A/CREATE Act changes followed as a new § 103(c).”
(internal citations omitted)).
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broader prior art searches could affect some nonprofits’ patenting
decisions.
D. Third-Party Challenge System
Prior to implementation of the AIA, the ex parte nature of
patent applications meant that third parties were generally
excluded from the application and review processes. However, a
narrow exception allowed third parties to submit prior art in
connection with a pending application, but not to comment upon,
explain, or argue about the submission. 65 The procedure was
designed to improve the quality of issuances by augmenting the
examiner’s prior art search, but it was rarely practiced. 66 The AIA
encourages expanded third-party prior art submissions by allowing
third parties who submit prior art to concisely describe the
relevance of the submitted art. 67
In addition to improving the quality of patents granted and
shortening the examination period, the third party submission
65

37 C.F.R. § 1.99 (2011).
LANDERS, supra note 5, at 27.
67
35 U.S.C. § 122(e)(2) (2011) (“Any third party may submit for
consideration and inclusion in the record of a patent application, any patent,
published patent application, or other printed publication of potential relevance
to the examination of the application (provided that certain requirements are
met) within the later of either six months from the challenged application’s
publication or from the USPTO’s first rejection of any claim in the
application.”). See also Preissuance Submissions by Third Parties,
AIARULEMAKING.COM,Ihttp://www.aiarulemaking.com/rulemaking-topics/
group-2/third-party-submission-prior-art-patent-application.phpi(“Another
change benefitting third parties is the extended time period that such
submissions will be accepted. This time period will be the earlier of: 1) the date
of a notice of allowance, or 2) the later of six months after the date of
publication or the date of a first Office action on the merits.”); USPTO, Press
Release 12-60: USPTO Encourages Third Parties to Participate in Review of
(Sep.
20,
2012),
Pending
Patent
Applications,
USPTO.GOV
http://www.uspto.gov/news/pr/2012/12-60.jsp (“[T]he submission by third
parties of prior art . . . allows the USPTO to tap directly into the U.S. innovation
community. Submissions provide a fuller, more exhaustive scope of materials
for examiners to review in determining the novelty of a given application. This
new mechanism will help ensure that truly novel, useful, and non-obvious
innovations obtain the intellectual property protection they deserve”).
66
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system allows parties, for a small fee, 68 to anonymously or openly
object to a patent’s issuance. Patent applicants thus must consider
strategies to defend against third-party submissions and identify
those parties as potential competitors, licensees, or partners. 69
E. Derivation Proceedings and Post-Grant Review
In conjunction with the move to FITF, and in an attempt to
improve administrative alternatives to litigation, the AIA revises
the means by which one challenges a patent’s validity. Previously,
the USPTO Board of Patent Appeals and Interferences conducted
interference proceedings—to ascertain priority of inventorship —
and patent reexamination procedures in both ex parte and inter
partes formats. These proceedings, and the changes to the system
under the AIA, will be examined in turn.
Under the first-to-invent system, a third party could challenge a
pending patent application or unexpired patent on the grounds that
the patentee was not the first to invent. If the claimed patents in
dispute met certain requirements, a panel of administrative judges
would conduct an interference proceeding to assess the evidence
(without discovery) and arguments of the parties. Interferences
were considered a cost-effective alternative to patent litigation, 70
though the mean cost of an interference proceeding has been

68

$180 per ten documents submitted. See Changes To Implement the
Preissuance Submissions by Third Parties Provision of the Leahy-Smith
America Invents Act, 77 F.R. 3, 453 (Jan. 5 2012) (to be codified at 37 C.F.R.
Part 1), http://www.gpo.gov/fdsys/pkg/FR-2012-01-05/pdf/2011-33811.pdf. See
also USPTO Third Party Preissuance Submission under CFR 1.290 Instructions
for
Paper
Filing,
available
at
http://www.uspto.gov/forms/
3prsubmission_instructions.pdf (last visited April 5, 2013).
69
See, e.g., Proposed New Rules Under AIA to Affect Third Party
Submissions of Prior Art, BRINKS, HOFER, GILSON & LIONE (May 31, 2012),
http://www.brinkshofer.com/news_events/3406-proposed-new-rules-under-aiaaffect-third-party-submissions-prior-art.
70
One estimate puts the average costs of a patent litigation at roughly
$2.5M, dependent on the amount in controversy and the type of technology
involved. American Intellectual Property Law Association, Report
of the Economic Survey, 2011, IPISC (2013), available at
http://www.patentinsurance.com/iprisk/aipla-survey/.
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estimated at over $650,000 71—likely a prohibitive figure for
nonprofits. 72 Although interferences will no longer be conducted
under the AIA, derivation proceedings will now determine whether
the first filer derived the invention from the petitioning party and
thus ascertain priority and inventorship. 73
A number of post-grant proceedings have defined the USPTO’s
role in adjudicating patent disputes. 74 Prior to implementation of
the AIA, a party challenging the validity of a patent outside of
litigation could request ex parte or inter partes reexamination by
the USPTO. 75 In a significant revision of the post-grant challenge
system, the AIA eliminates inter partes reexamination, replaces it
with post-grant review and inter partes review, and creates
supplemental examinations. These changes were designed to
increase the availability of cost-effective alternatives to patent
litigation. 76
Comporting with the AIA’s goal of producing better patents
and rectifying improper issuances, the post-grant and inter partes
review procedures are designed to expedite challenges. 77 Limited
71

Herbert D. Hart, III, An Interference: What, When, And How Much Does
It Cost?, AM. BAR ASS’N SECTION OF INTELLECTUAL PROP. LAW, 9 (Apr. 2007),
http://www.mcandrews-ip.com/files/article/Hart%20-%20Interference%20What
%20When%20How%20Much%20%20ABA%20IPL%2013%20Apr%2007%20
Logo.pdf.
72
This observation is based on comments from our survey respondents as
well as outside sources. See, e.g., Gene Quinn, Reform Doing Away with
Interference Proceedings & First to Invent, IPWATCHDOG (Mar. 26, 2010),
http://www.ipwatchdog.com/2010/03/26/reform-doing-away-with-interferenceproceedings-first-to-invent/id=9859/ (“With that cost [$($650,000]), not many
independent inventors or small businesses are going to be able to foot that
bill.”).
73
See LANDERS, supra note 5, at 56.
74
It should be noted that the USPTO does not adjudicate infringement
actions or breach of contract related to a patent. These are matters for the federal
and state courts.
75
Inter
Partes
Review,
AM.
INVENTS
ACT,
http://www.aiarulemaking.com/rulemaking-topics/group-2/inter-partesreview.php (last visited Feb. 6, 2014).
76
Id.
77
See Lawrence A. Stahl and Donald H. Heckenberg, The Scope and
Ramifications of the New Post-Grant and Inter Partes Review Proceedings
at the USPTO. FITZPATRICKCELLA.COM, http://www.fitzpatrickcella.com/
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discovery and a guaranteed hearing in post-grant review permit an
initial opportunity to address troublesome patents, while the
second window (nine months or more post-issuance) of inter partes
review protects patentees by narrowing the grounds for review and
types of evidence accepted. 78
Finally, the AIA creates supplemental examinations, which
enable patent owners to assess the strength of their patents—and
preempt third-party challenge or ex parte reexamination—by
submitting additional information that allows the USPTO to
“consider, reconsider, or correct information believed to be
relevant to the patent.” 79 These examinations also provide patent
owners with “amnesty” against charges of inequitable conduct—
information provided in a supplemental examination cannot be
used to render a patent unenforceable. 80
III. THE SURVEY: DATA ANALYSIS
To assess the AIA’s impact, realized or anticipated, on
nonprofit bioscience and global health research, we surveyed inhouse (n = 10) and outside attorneys (n = 7) representing
organizations throughout the region. The participating
organizations varied greatly in terms of age, size, available
resources, stated goals, and means of achieving those goals. For
example, while some institutions conduct basic research and seek
DB6EDC/assets/files/News/Fitz_PTO_1_4_8.pdf, (last accessed Feb. 7, 2014).
78
LANDERS, supra note 5, at 57.
79
35 U.S.C. § 257(a) (2011).
80
See LANDERS, supra note 5, at 54. Inequitable conduct is an affirmative
defense to a claim of patent infringement. Essentially, the defense asserts that
the patent is unenforceable due to the patentee’s fraudulent withholding of, or
submission of, material information to the USPTO during prosecution “but for
which” a patent would not have issued. See Therasense, Inc. v. Becton,
Dickinson & Co., 649 F.3d 1276, 1287 (Fed. Cir. 2011) (“To prevail on the
defense of inequitable conduct, the accused infringer must prove that the
applicant misrepresented or omitted material information with the specific intent
to deceive the PTO. The accused infringer must prove both elements—intent
and materiality—by clear and convincing evidence. If the accused infringer
meets its burden, then the district court must weigh the equities to determine
whether the applicant's conduct before the PTO warrants rendering the entire
patent unenforceable.”).
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licensing agreements to commercially develop promising
technologies, others determine how to best allocate grants to
further specific research or initiatives. Some larger entities with
greater resources have internal technology transfer and
commercialization departments that are not present in smaller
entities. 81
In this section, we discuss the qualitative responses of in-house
and outside counsel to our survey. For each area of the law, we
include a brief summary of the changes to that area, followed by
the questions we posed (in bold) and the responses by each group.
Please note that we sought global perspectives on the new law, as
distinct from the specific concerns of any particular organization.
Our data set represents cumulative, qualitative responses, and does
not represent the views of any particular organization.
A. First-Inventor-To-File
The AIA converts the patent priority system from first-toinvent to FITF. We first surveyed respondents on the transition to
FITF and its effects on nonprofit R&D and patent practices:
1. In your opinion, will FITF impact nonprofit organizations’
research and development? Why or why not?
In-house counsel generally answered that FITF will probably
not impact nonprofit R&D for two reasons. First, research
scientists at nonprofit organizations are generally not focused on
patenting their inventions; rather, they are driven by a desire to
expand knowledge and make beneficial discoveries. Because most
nonprofit research is funded by grants, scientists focus mainly on
publishing and writing grant proposals.
Second, when nonprofit organizations decide to protect their
biotechnology inventions, internal practices already follow the
international first-to-file and absolute novelty standards. For this
reason, if research produces a seemingly novel innovation, the
81

The respondents to our survey pointed out that even well-funded private
nonprofits possess far fewer resources than a large, state-funded research
university.
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nonprofit organization has typically filed a provisional application
to secure a patent placeholder before any disclosure is made. For
most respondents, then, adherence to best practices will mitigate
the effects of FITF on nonprofit research and development.
However, some in-house respondents noted that the AIA might
impact research and development by increasing pressure to “race
to the USPTO” to file cover sheet provisional applications. The
problem with this scenario is that the provisional application,
produced under pressure and probably with a bare minimum of
data to support the disclosure, will not satisfy the first-paragraph
requirements of § 112 82 (written description 83 and enablement 84).
82

The disclosure requirements under 35 U.S.C. § 112, ¶ 1 include written
description, enablement, and best mode. Specifically, that provision states that
the specification “shall contain a written description of the invention, and of the
manner and process of making and using it, in such full, clear, concise, and
exact terms as to enable any person skilled in the art to which it pertains [. . .] to
make and use the same, and shall set forth the best mode contemplated by the
inventor or joint inventor of carrying out his invention.” 35 U.S.C. § 112 (2011)
(emphasis added).
83
The written description requirement has several policy objectives. In
Ariad, the court held that there is a separate written description and enablement
requirement under 35 U.S.C. § 112, first paragraph. Ariad Pharmaceuticals, Inc.
v. Eli Lilly and Co., 598 F.3d 1336, 1341 (Fed. Cir. 2010) (en banc). The written
description requirement has several policy objectives. “[T]he ‘essential goal’ of
the description of the invention requirement is to clearly convey the information
that an applicant has invented the subject matter which is claimed.” In re Barker,
559 F.2d 588, 592 n.4 (C.C.P.A.CCPA 1977). Another objective is to put the
public in possession of what the applicant claims as the invention. See Regents
of the Univ. of Cal. v. Eli Lilly, 119 F.3d 1559, 1566, (Fed. Cir. 1997), cert.
denied, 523 U.S. 1089 (1998). The written description requirement implements
the principle that a patent must describe the technology that is sought to be
patented; the requirement serves both to satisfy the inventor’s obligation to
disclose the technologic knowledge upon which the patent is based, and to
demonstrate that the patentee was in possession of the invention that is claimed.
Capon v. Eshhar, 418 F.3d 1349, 1357 (Fed. Cir. 2005).
84
To satisfy the enablement requirement under 35 U.S.C. § 112, first
paragraph, a patent application must provide sufficient disclosure to enable a
person skilled in the art to make and use the claimed invention. One skilled in
the art would be enabled to practice the claimed invention if it would not require
undue experimentation to make and use the claimed invention and the claims are
not of undue breadth in view of the scope of the disclosure provided by the
specification. The Wands factors are considered by courts when determining
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As such, some anticipate that nonprofit organizations will respond
to FITF by tightening internal procedures to make sure that
scientists do not disclose before filing and that the application is as
strong as possible.
Outside counsel generally agreed with the in-house position,
suggesting that FITF will not impact nonprofit organizations’
research because those organizations already follow international
standards. The grace period changes generate some uncertainty,
discussed infra, but the best practice for nonprofit organizations
remains to file early and often.
Outside counsel gave four reasons for this filing practice: first,
when considering the costs of patenting, which are low relative to
the high potential value of patent protection, inventors are advised
to err on the side of filing on the invention at its early stage of
development. 85 Second, they pointed out that novelty and
obviousness requirements incentivize early filing in order to
establish priority over prior art that may render the subject matter
anticipated or obvious. 86 Finally, outside counsel stressed that the
formerly common practice of “swearing behind” a prior art
reference to prove an earlier date of invention would no longer be
an option under the FITF. One caveat that outside counsel
highlighted was that the pressure to be the first to file may affect
the quality and scope of the disclosure made. That is, the
disclosure may not support future claims that would have benefited
from the earlier priority date. The practice of filing early and often
could potentially increase the frequency of applications and affect
whether there is sufficient evidence to support a determination does not satisfy
the enablement requirement and whether any necessary experimentation is
“undue.” In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
85
See, e.g., Christopher A. Cotropia, The Folly of Early Filing in Patent
Law, 61 HASTINGS L.J. 65, 69 (2009).
86
See Lee A. Hollaar, LEGAL PROTECTION OF DIGITAL INFORMATION IN
CHAPTER 4: AN OVERVIEW OF PATENTS: VI—ANTICIPATION AND OBVIOUSNESS
(2002), available at http://digital-law-online.info/lpdi1.0/treatise57.html (last
accessed Feb. 7, 2014) (“If a claim reads on a single item of prior art – a printed
publication or a product – then that item of prior art “anticipates” the claim must
be rejected under Section 102 […]Section 103 bars a claim if it is obvious based
on a combination of two or more items of prior art, or differs in an obvious way
from an item of prior art.”)
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resource allocation; thus, the next question we asked was the
following:
2. In your opinion, will the FITF system affect when provisional
or nonprovisional applications are filed? Why or why not?
In-house counsel generally felt that the FITF system would not
affect when nonprofit organizations file applications for three
reasons. First, they recalled that nonprofits have long practiced
under international first-to-file standards. Second, frequent filing
practices have been in place to account for ongoing disclosures by
their scientists. Third, budget constraints mean that the number of
applications filed is unlikely to increase.
A few respondents again suggested that the “race to file” under
FITF might diminish the value of provisional applications. As
noted supra, there is a danger that quickly filed provisional
applications might not satisfy § 112. Under pre-AIA law, it was
standard practice for biotechnology inventors to record a plan for a
project and use that as the date of conception. 87 The inventor
would then work diligently to make and test the invention before
filing an application. 88 However, under the AIA, this approach
creates a risk that the first inventor is blocked from obtaining a
patent by another’s patent application or publication. 89 Therefore, a
rush to produce and file an application before the invention’s
reduction to practice may be the new standard.
Even if the inventor is the first to file, the application will be
vulnerable to rejection by the PTO—or, if a patent issues, to later
validity challenges—if the initial disclosure does not sufficiently
describe the invention to show that the inventor was actually in
possession of the invention at the time of application. 90 Thus, for
an inventor to claim the benefit of a provisional filing date, the
87

George Yu, How the First-To-File Provisions of the America Invents Act
(Feb.
1,
2012),
Will
Affect
Biotechnology,
SCHIFFHARDIN
http://www.schiffhardin.com/File%20Library/Publications%20(File%20Based)/
PDF/yu_sfdj_020112.pdf.
88
Id.
89
Id.
90
Id.
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provisional application must fully support the claims included in
the nonprovisional patent application. The claims must be
described and enabled by the provisional application, and an FITFinduced rush to file might compromise the patentability and value
of an invention.
Outside counsel were split on this question. Some believed that
nonprofit organizations would change patent filing practices due to
FITF for three reasons. First, nonprofit organizations might
increase the number of provisional applications that are filed in
order to secure patent protection in the United States, even though
foreign protection would be jeopardized under the international
absolute novelty standard. 91 The one-year grace period should
continue to give U.S. applicants time to prepare and file their
applications after disclosure. Consequently, some outside counsel
predicted an increase in early provisional applications filed
immediately after disclosure.
Second, the need for selectivity and resource management
under FITF will be exacerbated by the generally poor economic
environment, which may further depress nonprofits’ ability to file
early and often. Although the filing fee for a provisional
application in the United States is relatively low, 92 nonprofit
91

See European Patent Office, European Patent Convention Art. 54(2)
available
at
http://www.epo.org/law-practice/legaltexts/html/epc/2013/e/ar54.html (“The state of the art shall be held to comprise
everything made available to the public by means of a written or oral
description, by use, or in any other way, before the date of filing of the European
patent application.”).
92
A provisional application filing fee is $250 ($125 for small entities),
compared with $1,250 for a nonprovisional application. Under 35 U.S.C. §
41(h)(1), fees charged under 35 U.S.C. § 41(a), (b), and (d)(1) shall be reduced
by 50 percent with respect to their application to any small business concern as
defined under § 3 of the Small Business Act, and to any independent inventor or
nonprofit organization as defined in regulations issued by the Director. 35
U.S.C. § 41. The reduced fees include patent application filing fees including the
basic filing fee, search fee, examination fee, application size fee, and excess
claims fees (37 C.F.R. § 1.16) extension of time, revival, and appeal fees (37
C.F.R. § 1.17), patent issue fees (37 C.F.R. § 1.18), statutory disclaimer fee (37
C.F.R. § 1.20(d)), and maintenance fees on patents (37 C.F.R. § 1.20). See
USPTO, MPEP § 509.02, available at http://www.uspto.gov/web/offices/
pac/mpep.
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organizations still have nominal budgets that restrict the number of
provisional applications filed. 93 Because biotechnology patents are
generally protected worldwide, and because nonprofit
organizations have restricted budgets, these organizations will need
to exercise even more care when deciding where to file for a
patent. 94 Finally, the number, type, and timing of patent
applications filed depend on the nonprofit organizations’
intellectual property strategy. As of this writing, two pressing
questions for patent applicants are whether to file a provisional
application before March 16, 2013 and whether to switch an
existing provisional application to nonprovisional status before
March 16, 2013. 95
Other outside counsel believe that FITF will not have an
impact on when nonprofits file for two reasons, both related to
existing best practices. First, the current practice of filing under an
international first-to-file regime suggests that disclosure
management will not change much in response to FITF. Second,
investing resources to file a supportive provisional application that
satisfies § 112 should be the primary concern, even though
frequent filing is almost equally important. To recall, only those
93

For a complete list of filing, prosecution and maintenance fees, see
USPTO,
Fee
Schedule,
http://www.uspto.gov/web/offices/ac/qs/ope/
fee010114.htm (last revised Jan. 16, 2014).
94
The U.S. 2011 Global Patent & IP Trends Indicator: An in-depth look at
the foreign filing strategies of U.S. patent owners, INNOVIA (2011),
http://de.inovia.com/news/110228-inovia-Global-Patent-IP-Trends.jsp. A 2011
survey of nearly 150 companies, universities, and nonprofits that assessed the
impact economic conditions on global IP strategy and outlook reported that
nearly 60 percent of respondents are working on a reduced IP budget and many
are taking further steps to reduce patent costs. Forty-five percent of those
surveyed did not file into Japan in 2010 because of the high cost and low costto-benefit ratio; that is, the patent owner had to justify the success rate of getting
a patent in Japan, (approximately 20 percent) in light of the high filing cost. Due
to such high costs, companies tend to file in China for foreign protection,
reserving only extremely valuable filings for Japanese foreign jurisdiction.
95
This means that if the provisional application was converted after the
March 16 changeover date, any claim directed to disclosure that was not
supported by the original first-to-invent provisional application will be treated
under the FITF regime. See Leonid Kravets, First-to-File Patent Law Is
Imminent, But What Will It Mean?, TECHCRUNCH (Apr. 8, 2013),
http://techcrunch.com/2013/02/16/first-to-file-a-primer/.
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aspects of an invention that are supported by the provisional
disclosure will receive the benefit of the provisional priority date. 96
B. Prior Commercial Use and the University Exception
The AIA expands the prior commercial use defense to include
all manner of patented inventions. 97 This defense to a claim of
infringement derives from commercial use of the invention prior to
another’s patenting the invention, 98 and is an option for securing
continued use without fear of infringement. 99 Under the AIA,
instead of obtaining patent protection and disclosing the invention,
a user may practice the invention secretly and, if challenged, rely
on the prior commercial use defense to avoid liability. 100 With this
in mind, we asked:
1. In your opinion, will nonprofit organizations benefit from the
prior commercial use defense? Why or why not?
In-house counsel mostly answered that nonprofits would not
benefit from the commercial use defense because they are not
generally involved in “commercial” activity. Further, nonprofits
are infrequent targets for patent litigation due to their public profile
and relative lack of money. Hence, a defense to infringement
claims is unlikely to be of special interest to nonprofits. However,
one respondent opined that the AIA introduces uncertainty by
failing to specifically define “commercial process.” Though the
statutory language and legislative history support a broad
interpretation of the term, 101 the specific activities that will be
96

Timothy D. Casey & Juan C. Quiroz, What Innovators Need to Know–
and Need to Do–Under the America Invents Act, AMERICAN INNOVATORS FOR
PATENT REFORM, at 4 (Jan. 2012), available at http://www.aminn.org/files/
WhitePaper-AmericaInventsAct-Jan2012-2.pdf.
97
Id.
98
35 U.S.C. § 273(a) (2011).
99
Michael Dixon, The Sweeping Changes of the 2011 America Invents Act,
WESTLAW, at 7 (2012), http://www.mofo.com/files/uploads/images/120206patents-21st-century.pdf.
100
Id.
101
Craig R. Smith, The Prior Use Defense Under AIA, LAW 360 (Nov. 9,
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protected under this provision are uncertain and will likely be
determined through litigation.
A minority of outside counsel believed that the prior
commercial use defense’s university exception may benefit
nonprofit organizations when a university was involved in the
research project or if the nonprofit was determined to have
“university” status. Some also expected that where the public was
the intended beneficiary of the prior use, as generally occurs at
nonprofit research organizations like hospitals, the use will be
deemed commercial for the purpose of obtaining the defense.
The defense may also benefit nonprofits in the context of
licensing—if the defense is transferrable to a licensee, patents may
hold much greater value. Although the general rule is that the prior
user defense is personal and cannot be transferred in isolation, it
can be transferred as part of a larger good faith sale of the business
or line of business, which may include licenses. 102 How this
applies in the licensing context remains to be seen. The attorneys
also stressed that the prior user defense cannot be raised against
universities.
In response to concerns that the prior commercial use defense
would stifle innovation at universities, the legislature enacted the
university exception, preventing assertion of the prior use defense

2011),
http://www.lalaw.com/news-events/publications/upload/THE-PRIORART-DEFENSE-UNDER-AIA.pdf. 35 U.S.C. § 273(c)—entitled “Additional
commercial uses”—sets forth two qualifying commercial uses: (1) use or
marketing during a premarketing regulatory review period, and (2) nonprofit
laboratory use by universities, hospitals, and other nonprofit entities. The
legislative history suggests that commercial use may begin early in the use or
development of the technology. 35 U.S.C. § 273(c) (2011). Senator Leahy, one
of the co-sponsors of the patent reform bill, stated that the prior use defenses
vests when “innovative technology is first put into continuous internal use in the
business of an innovator’s enterprise with the objective of making a commercial
product.” See S. Doc. No. S5427 Senate (Sept. 8, 2011), available at
http://www.gpo.gov/fdsys/pkg/CREC-2011-09-08/pdf/CREC-2011-09-08senate.pdf.
102
See Peter A. Nieves, A Stronger Patent Infringement Defense Due To
Prior User Rights, SHEEHAN PHINNEY (Feb. 21, 2013) http://www.sheehan.com/
publications/good-company-newsletter/A-Stronger-Patent-InfringementDefense-Due-To-Prior-User-Rights.aspx.
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against a university or its technology transfer organization. 103
However, the limiting language 104 of the exception appears to
revive the defense against patents for inventions related to stem
cell research or human cloning, as well as any other research areas
that are prohibited from receiving federal funding. 105
2. In your opinion, how will the university exception benefit or
disadvantage nonprofit organizations?
In-house counsel were split on this question. Some believed
that the exception only covers universities and not other nonprofit
organizations, which accounted for the bulk of our respondents.
However, others believed that this protection may be available to
non-university nonprofit organizations or licensees that foster
collaborative relationships with universities. The scope of the
exception will probably be determined by litigation. In-house
respondents’ responses were limited, which may reflect a lack of
familiarity with this AIA provision, the infrequency of patent
litigation involving nonprofits, or both.
Outside counsel largely anticipate that the exception will
103

USPTO, REPORT ON THE PRIOR USER DEFENSE, 37 (2012), available at
http://www.uspto.gov/aia_implementation/20120113-pur_report.pdf.
104
This exception does not apply “if any of the activities required to
reduce to practice the subject matter of the claimed invention could not have
been undertaken using funds provided by the Federal Government.” 35 U.S.C.
§ 273(e)(5)(B) (2011).
105
Patents owned by universities or technology transfer organizations are
subject to an exception from the expanded prior user defense, but this exception
does not apply “if any of the activities required to reduce to practice the subject
matter of the claimed invention could not have been undertaken using funds
provided by the federal government.” See Brad D. Pedersen, US Patent Reform:
What Really Changes , PATTERSON THUENTE IP, (Sept. 23, 2011), available at
http://www.ptslaw.com/PatentReformSummaryOverviewWhitepaper.pdf. The
National Institute of Health federal grant guidelines prohibit research funding
for human embryonic stem cells (hESCs), the derivation of stem cells from
human embryos, or using hESCs derived from other sources, including somatic
cell nuclear transfer, parthenogenesis, and/or in vitro fertilization embryos
created for research purposes. See NIH Grants Policy Statement, NAT’L INST. OF
HEALTH
(Oct.
2012),
http://grants.nih.gov/grants/policy/nihgps_2012/
nihgps_ch4ch4index.htm.
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benefit both university and non-university nonprofits by
incentivizing relationships with universities. However, a few
expect no impact because the defense is rarely invoked and has
seen little to no successful assertion. The USPTO Report on the
Prior User Rights Defense supports this expectation, noting that
while the Federal Circuit has decided thousands of appeals on
almost every imaginable patent doctrine, the Court has yet to
address prior user rights. 106
C. Prior Art Expansion and the Modified One-Year Grace Period
The AIA expands the pool of prior art both geographically and
categorically. Prior art now includes knowledge, use, or any
activities rendering the invention “otherwise available to the
public” in the United States or any other country. Further, the
inventor’s one-year grace period is modified. We wondered
whether navigating a larger pool of prior art might affect resourcelimited nonprofits and whether the changes to the grace period held
any special significance.
1. In your opinion, how will these changes affect nonprofit patent
strategies?
In-house counsel answered that the AIA’s prior art provisions
would not affect patent strategies for three reasons. First,
nonprofits have historically operated from an international patent
perspective in order to maximize the reach of beneficial
innovations. Protecting intellectual property in multiple markets
widens the potential pool of licensees and often enables the
nonprofit to effect change where it matters. For example, an
organization dedicated to fighting malaria in subtropical countries
106

Report on the Prior User Defense, USPTO, at 31 (2012),
http://www.uspto.gov/aia_implementation/20120113-pur_report.pdf (concluding
that while prior user rights have been available in the United States since 1999
for business method patents, “only one case has been reported in which this
defense has been raised,” and the court in that case did not reach the issue
because the defense was untimely raised).
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might limit its reach if it only pursued patent protection in the
United States. If an invention addresses a problem that exists in
both developed and developing countries, the nonprofit may
leverage patent protection into a licensing agreement whereby the
licensee reaps profits in advanced economies in exchange for
discounting or giving away the developed product in poorer
economies. Comprehensive patent protection across markets thus
encourages mutually advantageous licensing opportunities, so
international practices are favored.
Second, nonprofits rarely have the resources to conduct
comprehensive prior art searches. In-house attorneys in this
industry typically cannot focus solely on intellectual property, and
a quick survey of publicly available patent databases will not
suffice. Even subscriptions to patent-listing periodicals 107 may be
prohibitively expensive, and the likelihood of as-yet-unpublished
prior art cannot be assessed. A caveat exists where the innovation
in question is highly valuable and exists in a tightly defined field of
technology. In such circumstances, the likelihood of competition
and licensing potentials are both high, and the nonprofit may spend
more aggressively to obtain the patent.
However, given the nature of the technology, particularly
where the research concerns rare diseases, few commercial
“blockbusters” are anticipated. More often, attorneys must look to
cheaper sources of information. For example, the investigators at
these institutions often work in narrow fields and have a
comprehensive understanding of the relevant art. Given the largely
collaborative nature of the academic community, the likelihood
that unanticipated prior art exists is fairly low. Furthermore, the
academic journals that publish research advances act as a novelty

107

Subscription-based commercial patent databases such as Delphion,
MicroPatent, and LexisNexis provide updated lists of available patents,
applications, and other information relevant to the state of a given patent area.
The costs range widely from $181-361/mo (Delphion), to $7500/yr
(MicroPatent) (note: these prices reflect only a couple of a wide range of patent
prosecution products). See Delphion Subscription Comparison Overview,
DELPHION, http://www.delphion.com/products/research/products-compare2 (last
accessed Feb. 6, 2014); PatentWeb, MICROPATENT, http://www.micropat.com/0/
products_pw9809.html (last accessed Feb. 6, 2014).
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filter; because journals seek to publish only novel findings,
publication is a strong indicator of patentable novelty.
Third, due to licensing practices, nonprofits rarely need to
expend significant resources on prior art searches. Most licensing
deals are negotiated in the year following a provisional filing, and
if an exclusive license is given, the licensee assumes responsibility
for prosecuting the patent. 108 Whether the nonprofit or a licensee
pursues the patent, it is common practice to file a PCT
application 109 and allow an authorized patent assessor to provide
an initial determination on patentability. 110 For these reasons,
particularly under an FITF regime, nonprofits will continue to file
early and often.
Outside counsel largely echoed these points, but emphasized
that clients should be educated as to changes in the law, such as the
end of “swearing back” to defeat a prior art reference under the old
system. 111 Filing prior to disclosure was also stressed, though, as
discussed previously, the race to file might have the unintended
effect of increasing the number of “coversheet provisional”

108

The nature of the patent and the market largely determine whether a
given license is exclusive or nonexclusive. See University Technology Transfer:
Questions and Answers, UNIVERSITY OF CALIFORNIA TECHNOLOGY TRANSFER,
http://www.ucop.edu/ott/faculty/tech.html#6 (last accessed Mar. 30, 2013).
(“Patents which are broad in scope and can be used in multiple industries, or
patents that they are so basic that they form the building blocks for new
technologies are most likely to be licensed non-exclusively [while universities]
most frequently will grant exclusive licenses to patents that require significant
private investment to reach the marketplace or are so embryonic that exclusivity
is necessary to induce the investment needed to determine utility.”).
109
Under the Patent Cooperation Treaty of 1970 (PCT), inventors in
signatory states can file a unified PCT application to obtain a priority filing date
in all other signatory states. Subsequent additional measures to meet
jurisdictional requirements must follow to obtain actual patent protection. See
James R. Cartiglia, The Patent Cooperation Treaty: A Rational Approach to
International Patent Filing, 76 J. PAT. & TRADEMARK OFF. SOC'Y 261, 262-63
(1994).
110
Inventions claimed in PCT applications are vetted by an authorized
“International Searching Authority” (ISA) that issues to the applicant a written
opinion on the patentability of the invention. See id. at 268.
111
Lopez, supra note 50.
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applications, which risk failing the written description and
enablement requirements of § 112. 112
Only one outside attorney suggested that the expanded field of
prior art might depress the value of licensing agreements. Where
comprehensive due diligence has not been completed, the
expanded pool of prior art may represent increased uncertainty as
to the novelty and nonobviousness of the invention. Therefore,
licensees may attempt to shift this risk onto licensors with
contingency clauses addressing the possibility of claim rejection by
the USPTO or of a successful validity challenge. The nonprofit’s
response might include devoting more resources to prior art
searches or grouping riskier or less-attractive patents with safer or
more attractive patents in combined licensing agreements.
Going forward, challenges and questions remain with regard to
prior art. How “otherwise available to the public” is interpreted by
the MPEP 113 and by the courts may impact the way that nonprofit
research organizations share their work. If secret sales or offers to
sell are no longer prior art, patent-holders may be incentivized to
sell their inventions more freely, using non-disclosure language in
contracts as a shield. Additionally, the AIA allows unknown prior
art—given the benefit of an initial filing date despite only
becoming public in a USPTO publication eighteen months later—
to be used in assessing both the novelty and nonobviousness of a
claimed invention. 114 A larger pool of such art may affect patent
valuations or prosecution decisions.
However, there are hints as to what prior art might look like
under the AIA. In response to public commentary, the USPTO
suggested that “otherwise available to the public” would likely be
112

As mentioned supra, “coversheet” or “manuscript” provisionals refer to
applications that contain only a written description and relevant drawings of the
invention, as well as identifying information for the inventor. Such applications
are generally submitted shortly after invention to secure a provisional filing date.
See USPTO, PROVISIONAL APPLICATION FOR PATENT (Feb. 2011),
http://www.uspto.gov/patents/resources/types/provapp.jsp.
113
The USPTO directs its examiners on applying the law to patent
applications in the MPEP, available at http://www.uspto.gov/web/offices/
pac/mpep.
114
Robert A. Armitage, Understanding the America Invents Act and its
Implications for Patenting, 40 AIPLA Q.J. 1, 27.
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assessed under the Federal Circuit’s test: whether the material was
“available to the extent that persons interested and ordinarily
skilled in the subject matter of the art, exercising reasonable
diligence, can locate it.” 115
Further, comments of the AIA drafters suggest that secret sales
were not intended to become prior art. 116 Taking this history into
account, the USPTO has stated that it will interpret “the ‘or
otherwise available to the public’ residual clause of the AIA's 35
U.S.C. § 102(a)(1) as indicating that secret sale or use activity does
not qualify as prior art.” 117 This issue may still be resolved by the
courts, however, and is likely to be tested.
2. Do you anticipate that the grace period rule will affect the
collaborative nature of research and the quality of the resulting
work? Why or why not?
In-house counsel generally responded that collaboration would
not be affected, although few supporting details were provided. As
a group, they seemed less familiar with this change than did
outside practitioners. This may have been due to the fact that inhouse counsel practitioners do not specialize in patent law, or to
115

See USPTO, Examination Guidelines for Implementing the First
Inventor to File Provisions of the Leahy-Smith America Invents Act (Feb. 14,
2013),
https://www.federalregister.gov/articles/2013/02/14/2013-03450/
examination-guidelines-for-implementing-the-first-inventor-to-file-provisionsof-the-leahy-smith (citing Voter Verified, Inc. v. Premier Election Solutions,
Inc., 687 F.3d 1374, 1380 (Fed. Cir. 2012) and Bruckelmyer v. Ground Heaters,
Inc.,445 F.3d 1374, 1378 (Fed. Cir. 2006)).
116
See C.R., Senate, 23 CONG. REC. S5431 (daily ed. Sept. 8, 2011)
(statement of Sen. Kyl: “public uses and sales are prior art only if they make the
invention available to the public.”). See also 157 CONG. REC. S1496-S1497
(daily ed. Mar. 9, 2011) (statement of Sen. Leahy: § 102(a)(1) “was drafted in
part to do away with precedent under current law that private offers for sale or
private uses or secret processes practiced in the United States that result in a
product or service that is then made public may be deemed patent-defeating
prior art.”).
117
USPTO, Examination Guidelines for Implementing the First Inventor
to File Provisions of the Leahy-Smith America Invents Act, 78 Fed. Reg. 11060
(Feb. 14, 2013), http://www.uspto.gov/aia_implementation/FITF_Final_
Guidelines_FR_2-14-2013.pdf.
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inherent ambiguities in the statute. Patent education efforts within
the institution were identified as an asset, but the ability to
implement such efforts was resource-dependent. Larger nonprofits
had more highly developed patent education and communication
schemes, while entities with lesser means gave fewer seminars and
presentations to their employees. However, all in-house counsel
framed the question as one of strategic relevance: where freely
disseminating an invention better serves the goals of a research
organization than would a patent, the need for educating inventors
on the patent system diminishes. Likewise, where recouping costs
is not a concern—e.g., for low-overhead technologies like
antibodies—, adherence to best patent practices is accordingly less
important.
This may be changing, however. Counsel for one large entity
stated that potential faculty members increasingly inquire as to the
organization’s technology transfer practices. The possible reasons
for this interest were not speculated, but it is sensible for
researchers to consider how conducive the institution’s policies are
to conducting compelling research and securing scarce funding.
Patent infrastructure may be viewed as a limiting diversion of
resources; alternatively, a researcher’s proprietary interest might be
a motivating factor. It is common for investigators to maintain a
stake in the innovations their lab produces, and a patent may
function as a revenue stream or as an asset for investigator to “spin
off” to independently sell or license. 118
In sum, in-house counsel did not give detailed responses as to
whether the grace period changes would affect collaboration, but
the generally felt that any impact would be negligible. Familiarity
with international practices, including early filing and absolute
novelty requirements, is expected to mitigate any growing pains.
One in-house attorney stated that good collaborations are directed
by intellectual property concerns; however, it is unclear how well
the changes to the grace period are truly understood, and a few of
in-house attorneys assessed the grace period as a false safety net.
Outside counsel answered that collaboration could well be
118

See, e.g., Science and Policy Introduction: The New Spin on Spin-offs,
ORG. FOR ECONOMIC COOPERATION AND DEV., http://www.oecd.org/science/scitech/introductionthenewspinonspin-offs.htm (last visited Apr. 8, 2013).
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detrimentally affected by a poor understanding of the new rules.
Ambiguity in the grace period provision language has drawn
criticism, including an official comment by the Washington State
Patent Lawyers Association to the USPTO regarding the
difficulties of the new grace period provision to the USPTO. 119 An
ill-timed disclosure may compromise the value of the invention
and stifle an advance. On the other hand, the fear of such
disclosures may hinder collaborative efforts. Thus, outside
practitioners recommended educating clients about the law as
described in subsection 3 infra.
Even where inventors firmly understand the law, outside
counsel cited other areas of concern. One suggested that the need
for quick reactions by inventors under the AIA might render
collaborations more difficult, but acknowledged that this issue
might be mitigated by familiarity with international practices.
119

E-mail and attached letter from Amanda Carmany-Rampey, Ph.D.,
Chair, Patent Office Rules and Practices Committee, Washington State Patent
Law Association, to USPTO Undersecretary Kappos, Attention: Mary C. Till,
Senior Legal Advisor, Office of Patent Legal Administration, Office of the
Deputy Commissioner for Patent Examination Policy (Oct. 5, 2012), available
at http://www.uspto.gov/patents/law/comments/wspla_20121005-guid.pdf (“The
legislative history of the AIA indicates [intent] to protect inventors who
publically disclose their invention before filing a patent application by providing
a grace period. The proposed examination guidelines, however, practicably
eliminate this grace period for any third-party disclosures that are not verbatim
reproductions of a prior disclosure by the inventor or joint inventor . . . . The
interpretation of 35 U.S.C. § 102(b)(1)(88B) and 35 U.S.C. § 102(b)(2)(88B)
promulgated in the proposed examination guidelines unduly limits the
applicability of the prior art exceptions with respect to subsequent, nonderived,
third-party disclosures, such that the exceptions are practically meaningless. The
proposed examination guidelines do not cite any authority for this interpretation;
to the contrary, the proposed examination guidelines are directly in conflict with
the legislative history of the AIA. Further, the proposed examination guidelines
do not provide any examples of instances where two independent disclosures by
an inventor and a subsequent third party would not have "insubstantial changes"
or "trivial or obvious variations." Without further guidance, it is reasonable to
interpret the provisions of 35 U.S.C. § 102(b)(1)(88B) and 35 U.S.C. §
102(b)(2)(88B) as being applicable only in instances of verbatim reproduction, a
scenario likely already provided for under 35 U.S.C. § 102(b)(1)(A) and 35
U.S.C. § 102(b)(2)(A). Thus, it is unclear when, if ever, the prior art exceptions
under 35 U.S.C. § 102(b)(1)(88B) and 35 U.S.C. § 102(b)(2)(88B) would apply
under the proposed examination guidelines.”).
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Another perspective was that while the AIA incentivizes joint
research collaborations by permitting collaborators to discount
prior art by the other party, 120 the new disclosure rules place added
importance on careful drafting and negotiation of collaboration
agreements.
We noted that our in-house respondents represented a broad
spectrum of nonprofits in terms of size, goals, and resources.
Given the resource balancing act and other challenges imposed
upon nonprofits by the AIA, we wondered whether outside counsel
would provide different advice to nonprofits along this spectrum.
3. In light of these changes, how would you advise nonprofits at
various stages of their development?
Despite the inquiry, outside counsel did not address nonprofits
of any particular size or resource set. Rather, they simply stressed
adherence to best practices, including careful management of
disclosures, and noted the tension between filing early and often
and obtaining sufficient data to satisfy § 112—though strong
filings were prioritized over early filings. With respect to the FITF
system, counsel reiterated their comments as described previously.
The only emergent theme was an emphasis that under an
international filing system, pre-AIA practices, such as filing in a
foreign patent office before disclosing in the United States, are
now obsolete with respect to U.S. priority.
The lack of clarity surrounding the new prior art categories and
changes to the grace period also prompted the attorneys to stress
intra-organizational communication and schedule-keeping so that
any disclosure that is “available to the public” is preceded by a
provisional application. The danger of manuscript provisional
failing § 112 was reiterated, and filing early under FITF should be
secondary to filing a strong provisional. A continuation that claims
the priority date of the provisional application should be
continually updated so that the “original disclosure” supports all
relevant advances in a final nonprovisional application. Further,
any reliance on the one-year grace period was discouraged. If the
120

35 U.S.C. § 102(c) (2011).
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entity is involved in or seeking a collaboration, careful negotiation
and drafting of intellectual property terms, particularly regarding
disclosures and filing procedures, will be of paramount
importance. A comprehensive understanding of the relevant arts is
ideal, though this is a difficult goal to achieve.
Finally, outside practitioners emphasized the need to keep good
notebooks and records of invention. Careful note taking allows
inventors to track mistakes, avoid duplicative experimentation, and
accurately record both results and inventions.121 Moreover, while
interference proceedings are abolished by the AIA, good records
remain invaluable in derivation proceedings. Respondents
recommended that upon invention, an inventor’s notebook should
be signed and dated by a witness who understands both the
invention and the state of the art. Of course, the reality is that
notebooks will always be primarily for scientific purposes.
Adherence to the best practices, from patent-conscious recordkeeping to properly managing disclosures, will be difficult to
ensure.
4. In your opinion, do your clients clearly understand what
constitutes prior art and “disclosures” under the new law? If
not, would you suggest taking steps to make this clearer?
While some in-house attorneys had previously stated that their
scientists were well versed in the basics of patent law, outside
practitioners felt differently. Several stated that new prior art
system, and not FITF, represented the most significant change
under the AIA. They recommended education programs at the
nonprofit level to explain the law—one attorney suggested
teaching programs for attorneys in CLE seminars—with a specific
emphasis on three points related to prior art and the grace period.
121

The Stanford University Office of Technology Licensing provides a list
of recommended best practices, including making sketches and written
description upon invention, temporally consecutive entries, and comprehensive
descriptions of experiments, equipment, and results. See Suggestions for
Keeping Laboratory Notebooks, STANFORD UNIV. OFFICE OF TECH. LICENSING,
http://otl.stanford.edu/inventors/resources/inventors_labnotebooks.html
(last
visited April 2, 2013).
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First, “disclosures” have grown in complexity. Public
disclosure can take myriad forms, including academic poster
sessions, written abstracts for research talks, PowerPoint slides,
and journal publications, all common features of academic
research. One attorney speculated that a web posting regarding a
future presentation might qualify. New media, such as blogs,
personal websites, and online academic journals should also factor
into disclosure considerations. Even patent-savvy innovators may
be caught by surprise, as some online journals now publish
uncorrected proofs of submitted articles before notice of formal
publication to the author. 122
Second, outside counsel cautioned that the grace period
changes are nuanced. As stated supra, the grace period does not
create a “first to publish” system where publishing prior to filing
defeats all subsequent art. Though the USPTO’s recently-released
final examination guidelines adopt a softer stance towards grace
period disclosures than had previously been discussed, 123 the
122

Online in less time, NATURE NEUROSCIENCE, Aug. 2001 at 767,
available at http://www.nature.com/neuro/journal/v4/n8/pdf/nn0801_767a.pdf.
123
In previous iterations of proposed examination guidelines, the USPTO
had suggested that disclosures that differed only in trivial or insubstantial ways
from the applicant’s initial disclosure would still become prior art against the
inventor. However, this stance has been changed in response to public comment.
See USPTO, EXAMINATION GUIDELINES FOR IMPLEMENTING THE FIRST
INVENTOR TO FILE PROVISIONS OF THE LEAHY-SMITH AMERICA INVENTS ACT,
F.R. 03450 (Office of the Federal Register Feb. 14, 2013), available at
https://www.federalregister.gov/articles/2013/02/14/2013-03450/examinationguidelines-for-implementing-the-first-inventor-to-file-provisions-of-the-leahysmith (“[T]hese examination guidelines also clarify, in response to the public
comment, that there is no requirement that the mode of disclosure by an inventor
or joint inventor (e.g., publication, public use, sale activity) be the same as the
mode of disclosure of the intervening disclosure, (e.g., inventor discloses his
invention at a trade show and also does not require the intervening disclosure is
in a peer-reviewed journal). Additionally, there is no requirement that the
disclosure by the inventor or a joint inventor be a verbatim or ipsissimis verbis
disclosure of the intervening disclosure. In addition, these examination
guidelines also clarify that in order for the exception based on a previous public
disclosure of subject matter by the inventor or a joint inventor to apply. These
guidelines also clarify that the exception applies to subject matter of the
intervening disclosure that is simply a more general description of the subject
matter previously publicly disclosed by the inventor or a joint inventor. . . . [I]f

218

WASHINGTON JOURNAL OF LAW, TECHNOLOGY & ARTS [VOL. 9:3

governing rules for which disclosures will fall within the grace
period and which will vitiate its protections remain to be seen.
Third, and crucially, the AIA grace period only extends to
disclosures made in the United States. 124 Publications available in
other jurisdictions immediately risk becoming prior art against the
inventor, and the global interests of the research organization must
factor into careful management of disclosures. Therefore, not all
public disclosures are per se protected by the grace period and
inventors must proceed carefully in making disclosures and in
seeking patents. Early filing, awareness of the grace period rules,
and general education regarding the AIA were stressed as critical
adaptations to the new law.
To facilitate this education, the best practice is open
communication between the nonprofit and a patent specialist.
Presentations or training by an attorney can teach guiding
principles to researchers, administration, and leadership and
explain the role that patents can play in fulfilling the organization’s
mission. Within an organization, vertical channels of
communication can promote early identification of valuable
innovations and careful recording habits. The attorneys
commented, however, that motivating researchers to implement
such practices, rather than focusing solely on publishing, would be
difficult.
D. Third-Party Challenge System

subject matter of the intervening disclosure is simply a more general description
of the subject matter previously publicly disclosed by the inventor or a joint
inventor, the exception in AIA 35 U.S.C. 102(b)(1)(B) applies to such subject
matter of the intervening disclosure. The specific comments on this issue are
also discussed in greater detail in the Responses to Specific Comments section.”
(See Comment 31 and Response).
124
A handful of other jurisdictions, including Canada and Australia,
independently provide a one-year grace period. For all intents and purposes,
U.S. filings receive grace period protection only in the United States. See Bill
Herman, The America Invents Act: practical upcoming implications—part II,
(Feb.
4,
2013),
http://www.lexology.com/library/
LEXOLOGY.COM
detail.aspx?g=3ab2164f-bb67-430d-b96b-5874f5db74be.
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The AIA enhances the ability for third party challengers to
challenge a pending patent application by submitting prior art to
the USPTO. Unlike pre-AIA law, the challenger can now include a
concise description of the prior art to direct the examiner. We
wondered whether nonprofits might react to an increased
likelihood of challenge, or whether they were now more likely to
participate in the challenge system.
1. In your opinion, will the third-party submission changes to the
AIA affect resource allocation in the patent process and the
resulting quality of the patented invention? Why or why not?
All counsel unanimously responded that while the challenge
system might make for better patents, it would have no effect on
how nonprofits allocated their resources or the quality of
inventions produced. Only one in-house attorney mentioned having
been involved with a challenge under the old system; the
overwhelming message was that nonprofits are rarely subjected to
such challenges and would not put any further resources into
shoring up a given invention or application simply due to this
provision of the AIA.
As with the prior art expansion, some outside attorneys noted
that the increased likelihood of third-party challenges might affect
patent valuations by potential licensees. Again, the nonprofit
response may be providing more data or performing more due
diligence than might have occurred prior to the AIA. Any such
effort is likely to be made easier in the collaborative and open
context of academic science, but still may constitute a burden for
nonprofits. Shifting the perspective, we asked whether nonprofits
were more likely to initiate or participate in third party challenges
under the AIA:
2. Do you feel that nonprofits are more likely to participate in
third party challenges? If so, how does this change your
counsel?
In-house counsel generally answered that while the third party
challenge system is more conducive to participation by nonprofit
organizations, expectations of participation were mixed. Generally
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speaking, these organizations are not as adversarial regarding their
work as their for-profit counterparts and are less likely to challenge
patents. Two attorneys stated that anything over the cost of an inhouse provisional application would be disfavored, making thirdparty challenges unlikely.
Others responded from a risk-analysis perspective, stating that
nonprofits may be involved when a licensee challenges a
competitor’s application. However, all attorneys agreed that
participation will only occur if it furthers the nonprofit’s goals. In
the reverse situation, a higher likelihood of challenges against a
nonprofit would probably encourage the nonprofit to license or
cross-license with the challenger in order to diffuse the challenge
and foreclose rejection by the USPTO or invalidation in litigation.
Outside counsel gave similar answers. A minority did suggest
that, of all the new pre- or post-grant challenge options, the thirdparty challenge system represented the cheapest and most
attractive option for nonprofits to participate. Moreover, the ability
to participate anonymously may prove an attractive feature for
image-conscious nonprofits.
However, this is balanced against the fact that even minimal
added costs may preclude participation by resource-limited
nonprofits. All outside counsel felt that challenges will not be a
priority for nonprofits and that any participation will be tied to
challenges by licensees. An exception may occur when the
nonprofit is heavily invested in a particular area of technology and
must, by necessity, influence the patent field.
One attorney cautioned that third party challenges are strategic
gambles. Should the challenger fail, the submitted prior art will
only strengthen the patent at issue and compromise any other
avenue for challenge on the same grounds. Therefore, potential
challenges should be evaluated against the strength of the patent as
well as challenger’s perceived chances in a post-grant proceeding
or in litigation.
Since the challenge system was opened in an attempt to induce
more participation, we wondered, whether a given nonprofit acts as
a challenger or a defensive party, if the challenge system under the
AIA is more equitable than it was previously.
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3. In your opinion, does the AIA provide a more equitable
challenge system for nonprofits? If so, why?
This question was not ideally drafted, as it elicited responses
about the entire pre- and post-grant challenge system rather than
specifically about third-party pre-issuance challenges. These
responses are addressed in the next section. To the extent that
third-party challenges were mentioned, all responding attorneys
felt that this mechanism was somewhat more equitable to resourcechallenged entities than the old system, but that on the whole, the
AIA had not made the challenge system more equitable. We then
proceeded to ask respondents specifically about the post-grant
proceedings:
E. Derivation Proceedings and Post-Grant Validity Challenges
1. The AIA has introduces four new challenge proceedings, each
with distinct features. Do you anticipate whether any, or all, of
the new proceedings will be attractive or helpful to nonprofits?
If so, why?
In-house counsel did not seem familiar with each of the new
provisions, but the overwhelming consensus was that, despite the
AIA’s efforts to open up the challenge system, nonprofit
organizations are still extremely unlikely to participate in any of
the various challenges. Licensing practices and other
considerations mean that nonprofits are unlikely to invalidate the
patents of others. Furthermore, the costs of post-grant proceedings,
while lower than litigation, are still prohibitive for nonprofits.
Universities also highlighted the difficulty in convincing the state
attorney general’s office that such proceedings would be a worthy
expenditure of taxpayer monies.
A few respondents mentioned that post-grant review, allowing
a wider scope of prior art discovery, seemed like the most
attractive post-issuance option but emphasized that participation
was very unlikely. Derivations, on the other hand, could be helpful
where collaborations go wrong or, alternatively, records of
collaboration might help in a derivation proceeding against a third
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party. One respondent made the illuminating point that while
nonprofits, particularly those working on “neglected” diseases, are
not often subject to suit in the current environment, changing
global economic circumstances may change this dynamic.
Specifically, those entities focused on treating tropical or
subtropical diseases, or afflictions not often considered in the
major pharmaceutical markets of Japan, Europe, and the United
States, could assume a more significant market role as countries
like China, India, and Brazil grow in population and economic
standing. In that event, market participants will scrutinize
heretofore less-valuable patents more closely and a deeper
understanding of the challenge system will be required of the
holder.
Outside counsel echoed their in-house counterparts,
emphasizing that since nonprofits are rarely the targets of patent
litigation, they are not especially concerned with litigation
alternatives. Post-grant review and inter partes review were
considered too expensive and typically occur so late in the timeline
of an invention that the nonprofit is no longer directly involved—
licensees are much more likely to use these offensive weapons.
One attorney pointed out that in the rare event that a nonprofit’s
patent is subjected to post-grant review, the nonprofit need not
spend on defense as they would in litigation; rather, the USPTO
conducts the proceeding with a presumption of validity. 125
From a defensive perspective, outside attorneys felt that the
new challenge system favored large corporations over nonprofit
inventors. Wealthy businesses can more easily afford the fees and,
thanks to the bifurcation of inter partes reexamination into postgrant review and inter partes review, now enjoy two opportunities
to challenge the patents of smaller entities. Respondents thus felt
that the new challenge system tilts in favor of large entities, is less
equitable for nonprofits, and is unlikely to produce better patents.
Finally, outside attorneys cited supplemental examinations as a
helpful way to prevent any future litigation and to clean up patent
prosecution history. Whether the costs will be borne by a licensee
or by the nonprofit remains to be seen. As with the changes to prior
125

35 U.S.C. § 282 (2011).
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art, the one-year grace period, and the third party challenge system,
a few outside attorneys speculated that the uncertainty created
might reflect on patent valuations and licensing deals. The actual
effect of this uncertainty is unclear and may take years of litigation
to provide a proper foundation for risk assessment.
CONCLUSION
Because nonprofit bioscience organizations have unique goals,
incentives, and challenges, we designed our survey to address
those aspects of the AIA that we felt were likely to pose special
challenges to them, either due to their collaborative and opensource nature or to the resource restrictions under which they often
operate. Our results met some of our expectations, defied others,
and added a great degree of nuance to our understanding of the
AIA and of the challenges faced by our respondents.
The AIA reshaped the face of patent law in the United States
by transitioning the priority system from first-to-invent to FITF.
We expected this transition to a high-pace FITF system to further
burden resource-limited nonprofits; we discovered, however, that
the transition’s effect was minimal because nonprofit organizations
(due to licensing practices and the international nature of their
guiding principles) were already practicing under the international
first-to-file standard. Outside counsel warned, however, that a race
to file could result in more manuscript provisional applications
being filed and failing to satisfy the patentability requirements of
§ 112.
In-house counsel further did not expect the expanded prior
commercial use defense to impact the generally non-commercial
nature of nonprofits’ research activities, but future litigation
regarding the definition of a “commercial activity” could add
relevance to this defense. Outside counsel foresaw that the defense,
as well as the university exception, could be beneficial to licensees
and may encourage collaboration with universities or other
academic nonprofits that may fall into that category.
Likewise, in-house counsel did not expect much impact due to
the changes regarding prior art and the one-year grace period. First,
in-house counsel expect that, in narrow and highly specialized
fields, their own inventors are effectively experts in the state of the
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art, meaning that while prior art may “expand” for inventors in
other sectors, scientists used to publishing, patenting, and
collaborating on an international level would not experience any
change due to an expanded field of prior art. Furthermore,
international absolute novelty practices have meant that filing early
is standard procedure, and to the extent that the U.S. one-year
period is taken advantage of, in-house counsel did not foresee any
specific change. Again, outside counsel urged greater resources be
put toward understanding the new laws. They recommended
education programs to relay to nonprofit innovators both the new
definition of “public disclosures”—specifically, the ramifications
of the “or otherwise available to the public” language in
§ 102(a)(1)—and the important nuances of the one-year grace
period. Whether a subsequent disclosure of the invention is
afforded the grace period or vitiates it is as yet unclear. For
scientists whose general goal is to share their research in a variety
of forums, proper disclosure management and careful collaboration
practices require careful consideration under the AIA. One outside
attorney pointed out that while nonprofit innovators may feel wellprepared for the AIA’s changes, the story may not be the same for
potential licensees, who might consider the prior art and grace
period rules as risks to patentability (e.g., whether the original
provisional has satisfied the § 112 requirements and supports a
final nonprovisional, or whether priority, novelty, or
nonobviousness becomes an issue under the new rules) that
depress the value of licenses. These complexities are not likely to
be sorted out in litigation for several years and may require an
adjustment period.
The AIA also introduced new ways in which the validity of
patents can be challenged both before and after issuance, yet
neither in-house nor outside counsel felt that third party challenges,
derivation proceedings, ex parte reexamination, post-grant review,
or inter partes review were particularly pertinent to nonprofits.
Nonprofit organizations do not challenge patents; rather, they are
interested in publishing, obtaining funding, and finding licensees
for their technology. Prior to the AIA, nonprofits rarely engaged in
any form of challenge because (a) they typically license out
enforcement rights to a wealthier commercial partner with better
incentives, and (b) they are rarely targeted for challenge or

2014]

THE IMPACT OF THE AMERICA INVENTS ACT ON
NONPROFIT GLOBAL HEALTH ORGANIZATIONS

225

litigation due to their narrow technological focus, lack of
commercial presence, and the public relations issues that a plaintiff
might expect in suing a nonprofit research organization. Although
the AIA attempts to encourage a more thorough vetting process by
expanding a variety of avenues for pre- and post-grant challenge,
our respondents expect no reaction from nonprofits. Challenged
entities are likely to seek licenses or cross-licenses with
challengers rather than risk invalidation, and nonprofits remain
extremely unlikely to engage as challengers. At this time, the
challenge system is most likely to affect nonprofits only indirectly,
with commercial partners and potential licensees reacting to the
uncertainties of an expanded challenge system.
In sum, our survey indicates that most effects of the AIA on
nonprofit science research and global health are likely to be
secondary, creating risks and uncertainties for commercial
licensing partners that may affect the ability of nonprofits to
accomplish their individual missions both in the United States and
around the world. We hope that this survey of nonprofit actors in
the Pacific Northwest provokes thought and provides guidance to
innovators—particularly with respect to disclosures—and patent
practitioners in this and other communities. Science will only
effect as much change as can be funded, and with the global
economy a state of flux, understanding all means—including
patents—for enabling laboratory advances, product development,
and effective delivery is indispensable to fulfilling nonprofits’
scientific and humanitarian missions.
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